Comments*

 
  • Drug Development

  • Events 

    Tuesday, September 30, 2014 | 8:30 AM - 5:00 PM

    Elucidating GPCR Functional Selectivity: Novel Opportunities for Drug Development

    Keynote Speaker: Nobel Laureate Robert J. Lefkowitz (Duke University Medical Center)
    Speakers: John A. Allen (Pfizer), Laura Bohn (The Scripps Research Institute), Marc G. Caron (Duke University Medical Center), Jonathan Javitch (Columbia University Medical Center), Terry Kenakin (University of North Carolina School of Medicine), Bryan L. Roth (University of North Carolina School of Medicine), JoAnn Trejo (University of California, San Diego), Jonathan D. Violin (Trevena Inc.)

    Hear academic, industry, basic and translational researchers, including Nobel Laureate Robert Lefkowitz (Duke University Medical Center) and discuss the development of functionally selective GPCR-biased ligands for CV and CNS disease drug discovery.

    Thursday, October 9, 2014 | 8:00 AM - 4:00 PM

    Targeting Key Vulnerabilities in Pancreatic Cancer

    Keynote Speakers: Neesha Dhani (Princess Margaret Hospital, Toronto), Steven D. Leach (Memorial Sloan Kettering Cancer Center)
    Speakers: Gregory Beatty (University of Pennsylvania Perelman School of Medicine), Mikala Egeblad (Cold Spring Harbor Laboratory), Douglas T. Fearon (Weill Cornell Medical College and Cold Spring Harbor Laboratory), Costas A. Lyssiotis (Weill Cornell Medical College ), George Miller (NYU Langone Medical Center), Michael Ports (Gilead Sciences)

    Pancreatic cancer patients currently have limited therapeutic options. This symposium explores breakthroughs in the pathogenesis and progression of pancreatic cancer, and efforts to exploit key vulnerabilities for novel therapeutic interventions.

    Friday, October 10, 2014 | 8:00 AM - 3:15 PM

    New Frontiers in the Neurobiology of Mental Illness

    Sold Out
    Keynote Speaker: The Honorable Patrick J. Kennedy
    Former United States Representative, Rhode Island; One Mind for Research; Kennedy Forum

    This conference will explore the translation of recent breakthroughs in neuroscience into therapies for the more than twenty-five percent of Americans suffering from mental illnesses such as schizophrenia, depression, fear and anxiety disorders, autism, and other psychiatric disorders. A keynote lecture by The Honorable Patrick J Kennedy will address strategies to simultaneously abolish the stigma surrounding mental illness in order to fully realize the potential of these new treatments to improve mental health.

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM

    Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Speaker: Michael S. Conte (University of California-San Francisco, San Francisco, CA), Milan Fiala (David Geffen School of Medicine at UCLA, Los Angeles, CA), Gabrielle Fredman (Columbia University, New York, NY), Bruce Levy (Harvard University, Brigham and Women's Hospital, Boston, MA), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Boston, MA), Mauro Perretti (William Harvey Research Institute, London, UK), Charles N. Serhan (Harvard University, New York, NY), Patricia J. Sime (University of Rochester School of Medicine, Rochester, NY), Rudy Tanzi (Massachusetts General Hospital, Charlestown, MA)

    Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.

    Saturday, November 15, 2014 | 11:00 AM - 4:00 PM

    Risky Business – A Pharmaceutical Industry Strategy Workshop

    Moderators: Florian Jehle (Catenion), Jan-Philipp Kruse (Catenion)

    This course gives professionals from inside and outside the pharmaceutical industry—including students and postdocs—a much better understanding of how the R&D and business development and licensing processes operate.

  • Past Events

    Monday, September 15, 2014 | 12:00 PM - 4:00 PM

    Click Chemistry in Biology and Medicine: New Developments and Strategies

    Keynote Speakers: Jim Paulson (The Scripps Research Institute), K. Barry Sharpless (The Scripps Research Institute)
    Speakers: Yimon Aye (Cornell University), David A. Spiegel (Yale University), Mingxuan Wu (Princeton University), Peng Wu (Albert Einstein College of Medicine)

    Click chemistry offers a reliable method for discovering chemical connectivity, with great potential in drug discovery and biomedical research. This symposium explores recent developments that offer new technologies for disease diagnosis and therapy.

    Thursday, June 26, 2014 | 7:45 AM - 6:00 PM

    Demyelination and Remyelination: From Mechanism to Therapy

    Keynote Speaker: Robin Franklin (Wellcome Trust – MRC Cambridge Stem Cell Institute, University of Cambridge)

    This translational conference will highlight biological and clinical findings in myelin development, new techniques for brain imaging and for screening molecular targets, and novel therapeutics that promote remyelination.

    Tuesday, May 20, 2014 | 8:30 AM - 5:00 PM

    Hot Technologies for Developing Next-Gen Biologics

    Speakers: Timothy Charlebois (Pfizer), David King (AnaptysBio Inc.), William M. Pardridge (Brain Research Institute, UCLA), Steven J. Projan (MedImmune), Sachdev Siddhu (University of Toronto), E. Sally Ward (UT Southwestern), Patrick C. Wilson (The University of Chicago), K. Dane Wittrup (Massachusetts Institute of Technology)

    New technologies are pivotal in developing next-generation biologics. This symposium highlights novel technologies in the discovery of new biologics, elucidating in vivo mechanisms of therapeutic proteins, and manufacturing and delivery processes.

    Friday, May 9, 2014 | 8:00 AM - 4:00 PM

    The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease

    Speakers: Carmela R. Abraham (Boston University School of Medicine), Eric H. Baehrecke (University of Massachusetts Medical School), Nir Barzilai (Albert Einstein College of Medicine), Jerry R. Colca (Metabolic Solutions Development Company), Brendan D. Manning (Harvard School of Public Health), Beth Stevens (Harvard Medical School), D. Martin Watterson (Northwestern University Feinberg School of Medicine), Haung Yu (Columbia University), Jeffrey W. Kelly (The Scripps Research Institute), Richard I. Morimoto (Northwestern University)

    Age is the major risk factor for Alzheimer's disease, and key pathways in aging biology offer targets for novel drugs. Explore recent advances in the science of aging and innovative drug discovery for Alzheimer's and other neurodegenerative diseases.

  • Publications 

    eBriefing

    Demyelination and Remyelination: From Mechanism to Therapy

    Keynote Speaker: Robin Franklin (Wellcome Trust – MRC Cambridge Stem Cell Institute, University of Cambridge)

    This eBriefing highlights biological and clinical findings in remyelination. It also features new techniques for imaging myelin and screening molecular targets, as well as therapeutics that promote remyelination.

    Annals

    Annals Reports

    Edited by Annals of the New York Academy of Sciences editorial staff

    This Annals volume presents three meeting reports: (1) Production and supply of high-quality food protein for human consumption: sustainability, challenges, and innovations; (2) Clinical and economic outcomes of nutrition interventions across the continuum of care; and (3) Antibody–drug conjugates: an emerging modality for the treatment of cancer.

    Volume 1321

    eBriefing

    The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease

    Organizers: Howard Fillit (Alzheimer's Drug Discovery Foundation), Kevin J. Lee (Lawrence Ellison Foundation), and Jennifer Henry (The New York Academy of Sciences)

    This eBriefing explores advances in the science of aging and in drug discovery for Alzheimer's and other neurodegenerative diseases.

    eBriefing

    Malaria 2014: Advances in Pathophysiology, Biology, and Drug Development

    Organizers: Johanna P. Daily (Albert Einstein College of Medicine), David A. Fidock (Columbia University Medical Center), and Jennifer Henry (The New York Academy of Sciences)
    Keynote Speakers: Jane M. Carlton (New York University), Rick M. Fairhurst (National Institute of Allergy and Infectious Diseases, NIH), and Terrie E. Taylor (Michigan State University)

    This eBriefing highlights a symposium held on World Malaria Day to examine breakthroughs in pathophysiology, drug development, and pre-erythrocytic and liver-stage biology.

  • Podcasts

    Podcast
    April 2, 2010

    More than a Yogurt Cup

    Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.

    Download (14 MB, 00:21:21)
    Podcast
    January 15, 2010

    Feeling the Light

    Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.

    Download (15 MB, 00:22:48)
    Podcast
    December 18, 2009

    No Small Matter

    We sit down with science photographer Felice Frankel and nanotechnology pioneer and Harvard chemist George Whitesides to hear about their new book on nanoscience, No Small Matter.

    Download (11 MB, 00:18:04)
    Podcast
    October 16, 2009

    Looking for the Key in P53

    Visit the lab of Hunter College's Jill Bargonetti, a biologist researching cancer. Her team studies P53, a natural tumor-suppressor protein found in our bodies with a Dr. Jekyll and Mr. Hyde personality.

    Download (11 MB, 00:17:20)
  • Webinar Archives

    Webinar Archive
    February 23, 2010

    Metabotropic Glutamate Receptors: Translation from Discovery to Clinical Trials

    Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.

    Webinar Archive
    October 27, 2009

    Is Alzheimer's Disease Type 3 Diabetes?

    What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.

    Webinar Archive
    April 28, 2009

    Protein Kinases: Structure-Guided Drug Discovery

    Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.

  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.